Supplementary Table 6. Associations between inflammatory markers and predictors of mortality or disease severity. Inflammatory marker risk groups tested for association with known predictors of mortality from or development of severe Covid-19 for the whole dataset (n=1,071). P values shown for strength of association determined via Pearson's chi-square test.

Inflammatory Marker	# of Comorbidities (0/1/2+, %)	<i>P</i> Value	# of Complications (0/1/2+, %)	<i>P</i> Value	Anti-cancer Therapy at Diagnosis (N/Y %)	<i>P</i> Value	Sex (F/M, %)	<i>P</i> value	Age (65/≥65, %)	<i>P</i> value
NLR					( ,					
NLR6	133/147/230 (26.1%/28.8%/45.1%) 86/141/299	.0001	191/176/111 (40.0%/36.8%23.2%) 117/205/165	.0001	216/274 (44.1%/55.9%) 282/228	.001	243/264 (47.9%/52.1%) 187/339	.0001	235/274 (46.2%/53.8%) 172/350	.0001
NLR≥6	(16.3%/26.8%/56.8%)		(24.0%/42.1%/33.9%)		(55.3%/44.7%)		(35.6%/64.4%)		(33.0%/67.0%)	
PLR	(10.070/20.070/00.070)		(21.070/12.170/00.070)		(00.070/11.170)		(00.070/01.170)		(00.070/07.070)	
PLR270	109/150/230 (22.3%/30.7%/47.0%)	0.064	163/177/115 (35.8%/38.9%/25.3%)	0.020	236/246 (49.0%/51.0%)	0.747	214/273 (43.9%/56.1%)	0.212	202/282 (41.7%, 58.3%)	0.069
PLR≥270	99/125/267 (20.2%/25.5%/54.4%)		134/183/152 (28.6%/39.0%/32.4%)		243/243 (50.0%/50.0%)		196/294 (40.0%/60.0%)		177/314 (36.0%/64.0%)	
OIS	( ,		(		(,		(		(	
OIS40	69/76/124 (25.7%/28.3%/46.1%)	0.010	104/102/46 (41.3%/40.5%/18.3%)	.0001	127/129 (49.6%/50.4%)	0.124	115/154 (42.8%/57.2%)	0.152	115/154 (42.8%/57.2%)	0.049
OIS≤40	71/91/222		88/130/134		205/162		142/240		135/249	
mGPS	(18.5%/23.7%/57.8%)		(25.0%/36.9%/38.1%)		(55.9%/44.1%)		(37.2%/62.8%)		(35.2%/64.8%)	
0	50/53/66		73/62/26		75/91		82/87		85/84	
1	(29.6%/31.4%/39.1%) 52/49/95	.001	(45.3%/38.5%/16.1%) 58/85/39	.0001	(45.2%/54.8%) 99/91	0.005	(48.5%/51.5%) 80/116	0.036	(50.3%/49.7%) 79/117	0.004
	(26.5%/25.0%/48.5%)		(31.9%/46.7%/21.4%)		(52.1%/47.9%)		(40.8%/59.2%)		(40.3%/59.7%)	
2	52/73/182		64/98/118		178/116		111/194		106/201	
PI	(16.9%/23.8%/59.3%)		(22.9%/35.0%/42.1%)		(60.5%/39.5%)		(36.4%/63.6%)		(34.5%/65.5%)	
0	45/43/54		62/54/20		59/80		70/72		73/69	
U	(31.7%/30.3%/38.0%)		(45.6%/39.7%/14.7%)		(42.4%/57.6%)		(49.3%/50.7%)		(51.4%/48.6%)	
1	102/149/295	0.002	126/209/170	.0001	245/282	.0001	218/326	0.139	209/332	0.001
	(18.7%/27.3%/54.0%)		(25.0%/41.4%/33.7%)		(46.5%/53.5%)		(40.1%/59.9%)		(38.6%/61.4%)	
2	24/43/73		26/54/51		94/40		58/82		43/97	
	(17.1%/30.7%/52.1%)		(19.8%/41.2%/38.9%)		(70.1%/29.9%)		(41.4%/58.6%)		(30.7%/69.3%)	

N: No; Y: Yes; F: Female; M: Male; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; OIS: OnCovid Inflammatory Score; mGPS: Modified Glasgow prognostic score; PI: Prognostic index